<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969110</url>
  </required_header>
  <id_info>
    <org_study_id>AEPIPD</org_study_id>
    <nct_id>NCT01969110</nct_id>
  </id_info>
  <brief_title>Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy</brief_title>
  <official_title>Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiba University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiba University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether perioperative immunonutrition has
      additional effects on cell-mediated immunity in patients undergoing pancreaticoduodenectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators reported that perioperative immunonutrition had no additional effects
      compared with preoperative immunonutrition in patients underwent colorectal surgery (Braga M,
      Gianotti L, Vignali A, Carlo VD. Preoperative oral arginine and n-3 fatty acid
      supplementation improves the immunometabolic host response and outcome after colorectal
      resection for cancer. Surgery. 2002; 132:805-14, PMID: 12464864). Object of this study is to
      investigate the additional effects of perioperative immunonutrition on cell-mediated immunity
      and incidence of infectious complication after pancreaticoduodenectomy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma resolvin E1, cell-mediated immunity</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>infectious complication rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Tumor</condition>
  <condition>Bile Duct Tumor</condition>
  <arm_group>
    <arm_group_label>Perioperative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral IMPACT (1 L/day) for 5 days before surgery and by enteral feeding after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preoperative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral IMPACT 1000ml/day for 5 days (1 L/day) before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral IMPACT</intervention_name>
    <description>Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery</description>
    <arm_group_label>Perioperative</arm_group_label>
    <arm_group_label>Preoperative</arm_group_label>
    <other_name>Oral IMPACT; Ajinomoto Pharma Co., Ltd, Tokyo, Japan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing pancreaticoduodenectomy

        Exclusion Criteria:

          -  age younger than 18 years old

          -  ongoing infection

          -  gastrointestinal obstruction

          -  respiratory dysfunction

          -  cardiac dysfunction

          -  hepatic dysfunction

          -  renal failure

          -  history of recent immunosuppressive or immunological disease

          -  preoperative evidence of widespread metastatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katsunori Furukawa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chiba University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katsunori Furukawa, MD</last_name>
    <phone>+81-43-222-7171</phone>
    <phone_ext>72235</phone_ext>
    <email>k-furukawa@umin.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daisuke Suzuki, MD</last_name>
    <phone>+81-43-222-7171</phone>
    <phone_ext>72234</phone_ext>
    <email>d-suzuki@umin.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8670</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katsunori Furukawa, MD</last_name>
      <phone>+81-43-222-7171</phone>
      <phone_ext>72235</phone_ext>
      <email>k-furukawa@umin.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2013</study_first_submitted>
  <study_first_submitted_qc>October 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiba University</investigator_affiliation>
    <investigator_full_name>Katsunori Furukawa</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Immunonutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

